Press Releases

19/04/2010

ActoGeniX appoints new Chief Executive Officer
09/10/2009

ActoGeniX completes Phase 2A clinical trial of AG011
20/08/2009

ActoGeniX receives IWT grant for treatment of oral mucositis and starts clinical trial with AG013
14/05/2009

ActoGeniX obtains IND approval for AG013
30/03/2009

ActoGeniX extends equity financing round to EUR 15.5 million
10/02/2009

ActoGeniX successfully completes equity financing round of EUR 13.5 million
11/09/2008

ActoGeniX announces the start of a Phase 2A clinical trial
14/05/2008

ActoGeniX completes manufacturing of its clinical product AG011 and prepares for phase 2 clinical trial
12/07/2007

ActoGeniX receives EUR 3 million from the Flanders government through IWT.
22/05/2007

Dr Pol Bamelis joins ActoGeniX Board of Directors
06/02/2007

ActoGeniX completes Series A equity financing round of € 20 million (~US$26 million)
24/01/2007

ActoGeniX appoints Patrick Dhaese as Vice President CMC Operations